Imatinib mesylate: A designer drug.
Artículo
en Inglés
| IMSEAR
| ID: sea-94040
ABSTRACT
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positive acute lymphatic leukemia. The efficacy of imatinib has geared up further research into development of designer drugs with molecular targets. This review gives a comprehensive description of the development, biology, utility, dosing, and limitations of imatinib mesylate.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Piperazinas
/
Pirimidinas
/
Cromosoma Filadelfia
/
Humanos
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Tumores del Estroma Gastrointestinal
/
Inhibidores de Proteínas Quinasas
/
Eosinofilia
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Idioma:
Inglés
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS